Yifeng Pharmary(SH:603939) Orient Securities·2025-09-19 11:48Investment Rating - The report maintains a "Buy" rating for the company with a target price of 31.46 CNY based on a 22x PE ratio for 2025 [2][5]. Core Insights - The company has adjusted its revenue forecasts for 2025-2027 downwards while increasing gross margin and expense ratio estimates. The revised earnings per share (EPS) projections are 1.43, 1.62, and 1.82 CNY for 2025, 2026, and 2027 respectively [2]. - The company is focusing on fine-tuning operations for profit optimization and anticipates growth in the new retail sector [1]. Financial Performance Summary - Revenue for 2023 is projected at 22,588 million CNY, with a year-on-year growth of 13.6%. For 2024, revenue is expected to be 24,062 million CNY, reflecting a 6.5% growth. The revenue forecast for 2025 is 25,616 million CNY, maintaining the same growth rate of 6.5% [4]. - Operating profit is expected to rise from 2,055 million CNY in 2023 to 2,566 million CNY in 2025, indicating a significant growth rate of 16.4% in 2025 [4]. - The net profit attributable to the parent company is projected to grow from 1,412 million CNY in 2023 to 1,737 million CNY in 2025, with a year-on-year growth of 13.6% [4]. - The gross margin is expected to improve from 38.2% in 2023 to 40.5% in 2025, while the net margin is projected to increase from 6.3% to 6.8% over the same period [4]. Market and Operational Strategy - The company has shifted its strategy from aggressive expansion to enhancing operational efficiency, closing underperforming stores, and focusing on profitable growth [9]. - The company has a total of 14,701 stores as of the first half of 2025, with a net increase of 17 stores, indicating a strategic focus on quality over quantity in store expansion [9]. - E-commerce and O2O (Online to Offline) business segments are showing strong growth, with B2C revenue reaching 4.1 billion CNY, up 88.5% year-on-year, and O2O revenue at 9.4 billion CNY, up 7.5% [9].